Cargando…

Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma

Detalles Bibliográficos
Autor principal:	Zhang, D.X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216277/ https://www.ncbi.nlm.nih.gov/pubmed/35754457 http://dx.doi.org/10.1016/j.iotech.2020.06.002

Ejemplares similares

Game changers: stories of the revolutionary minds behind game theory
por: Taschner, Rudolf
Publicado: (2017)

Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression
por: Matsuki, Ryota, et al.
Publicado: (2022)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
por: Bae, Sun Hyun, et al.
Publicado: (2023)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2022)

The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
por: Lieb, Sabine, et al.
Publicado: (2023)

Is Omicron the game changer of COVID-19 infection in children?
por: Liang, Qiwei, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
por: Hou, Yanli, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
por: Endo, Kei, et al.
Publicado: (2022)

Medical Emergency Team: A Game Changer in the Wards
por: Chandrasegarane, Saranya, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
por: Wang, Yulei, et al.
Publicado: (2021)

SDF − a game changer?
por: Remtulla, A.
Publicado: (2020)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
por: Cheon, Jaekyung, et al.
Publicado: (2023)

HTX-011: Another game changer multimodal analgesic or an ephemeral, experimental drug!
por: Nair, Abhijit, et al.
Publicado: (2020)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
por: Sinner, Friedrich, et al.
Publicado: (2022)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023)

Clinical audit and lifelong reflective practice as game changers to integrate medical education and practice
por: Biswas, Rakesh
Publicado: (2015)

Drones for Medical Supply During Disaster: A Game Changer in “Health for All” Policy
por: Das, Nikunja Kumar, et al.
Publicado: (2023)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2015)

Game Changers
Publicado: (2015)

Game changers
Publicado: (2016)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
por: AL Zahrani, Ali, et al.
Publicado: (2021)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling
por: Krug, Sebastian, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
por: Itoh, Shinji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bvkk0dnhm2l0didvpumkkk67cb